Advertisement
ARMP vs NERV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARMP is a StrongBuy and NERV is a Hold.
ARMP's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ARMP turned positive on October 20, 2026. Looking at past instances where ARMP's MACD turned positive, the stock continued to rise in 44 of 47 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARMP's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 66 cases where ARMP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +21.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARMP advanced for three days, in 217 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
ARMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARMP as a result. In 93 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The 10-day moving average for ARMP crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ARMP entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.555) is normal, around the industry mean (2.973). P/E Ratio (-0.652) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.260) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ARMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NERV's Indicator enters downward trend
The Aroon Indicator for NERV entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 241 similar instances where the Aroon Indicator formed such a pattern. In 209 of the 241 cases the stock moved lower. This puts the odds of a downward move at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for NERV turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NERV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where NERV advanced for three days, in 193 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
NERV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.515) is normal, around the industry mean (2.973). P/E Ratio (-0.064) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. NERV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NERV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARMP | NERV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 76 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 45 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 89 | 92 | |
P/E GROWTH RATING 1..100 | 13 | 97 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NERV's Valuation (45) in the Biotechnology industry is in the same range as ARMP (59). This means that NERV’s stock grew similarly to ARMP’s over the last 12 months.
NERV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARMP (100). This means that NERV’s stock grew similarly to ARMP’s over the last 12 months.
NERV's SMR Rating (100) in the Biotechnology industry is in the same range as ARMP (100). This means that NERV’s stock grew similarly to ARMP’s over the last 12 months.
ARMP's Price Growth Rating (89) in the Biotechnology industry is in the same range as NERV (92). This means that ARMP’s stock grew similarly to NERV’s over the last 12 months.
ARMP's P/E Growth Rating (13) in the Biotechnology industry is significantly better than the same rating for NERV (97). This means that ARMP’s stock grew significantly faster than NERV’s over the last 12 months.
| ARMP | NERV | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 87% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 85% | N/A |
| Momentum ODDS (%) | 2 days ago 87% | N/A |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Advances ODDS (%) | 8 days ago 86% | 18 days ago 80% |
| Declines ODDS (%) | 10 days ago 87% | 5 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARMP’s FA Score shows that 1 FA rating(s) are green while NERV’s FA Score has 0 green FA rating(s).
- ARMP’s FA Score: 1 green, 4 red.
- NERV’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARMP’s TA Score shows that 5 TA indicator(s) are bullish while NERV’s TA Score has 3 bullish TA indicator(s).
- ARMP’s TA Score: 5 bullish, 4 bearish.
- NERV’s TA Score: 3 bullish, 3 bearish.
Price Growth
ARMP (@Biotechnology) experienced а +11.65% price change this week, while NERV (@Biotechnology) price change was -0.83% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was -16.27%, and the average quarterly price growth was -16.72%.
Reported Earning Dates
ARMP is expected to report earnings on Nov 11, 2026.
NERV is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+1.28% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ARMP and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARMP has been loosely correlated with RANI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ARMP jumps, then RANI could also see price increases.
| Ticker / NAME | Correlation To ARMP | 1D Price Change % | ||
|---|---|---|---|---|
| ARMP | 100% | +12.75% | ||
| RANI - ARMP | 44% Loosely correlated | -2.88% | ||
| NERV - ARMP | 43% Loosely correlated | +0.42% | ||
| DMRA - ARMP | 34% Loosely correlated | +0.84% | ||
| SION - ARMP | 32% Poorly correlated | -1.81% | ||
| ARTV - ARMP | 30% Poorly correlated | -4.47% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DIVB | 71.64 | 1.86 | +2.67% |
| iShares Core Dividend ETF (DIVB) | |||
| MARU | 30.13 | N/A | N/A |
| AllianzIM U.S. Equity Buffer15 Uncapped Mar ETF (MARU) | |||
| ECML | 40.57 | -0.04 | -0.11% |
| Euclidean Fundamental Value ETF (ECML) | |||
| QVMM | 33.93 | -0.11 | -0.32% |
| Invesco S&P MidCap 400 QVM Multi-factor ETF (QVMM) | |||
| ARCX | 5.57 | -0.14 | -2.45% |
| Tradr 2X Long ACHR Daily ETF (ARCX) | |||